Insider trades
Oleg Nodelman, Director of Aktis Oncology AKTS, has filed 31 purchases and 0 sales on the open market. Over the past 12 months that comes to a net purchase of $40M. The latest trade was on 01/12.
Oleg Nodelman
Director
- Company
- Aktis Oncology AKTS
- First filing
- 23/05/02
- Trades
- 45 trades
- Buys / sales
- 31 / 0
- 12-month net buying
- $40M
- Last trade
- 01/12
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
AKTS | Open-market buy | 01/12 | 01/12 | 2,222,222 sh2 trades | $18.00avg. | $39,999,996 | No record |
ZYME | Open-market buy | 25/05/15–25/05/19 | 25/05/19 | 55,421 sh2 trades | $11.47avg. | $635,533.68 | +0.3% |
ZYME | Open-market buy | 25/04/16–25/04/17 | 25/04/18 | 128,713 sh2 trades | $11.31avg. | $1,456,150.68 | +0.7% |
ZYME | Open-market buy | 25/04/03–25/04/04 | 25/04/07 | 317,208 sh2 trades | $11.43avg. | $3,624,129.26 | +1.8% |
ZYME | Open-market buy | 25/03/31–25/04/02 | 25/04/02 | 127,415 sh3 trades | $11.75avg. | $1,497,263.55 | +0.7% |
ZYME | Open-market buy | 25/03/25–25/03/26 | 25/03/27 | 97,349 sh2 trades | $12.61avg. | $1,227,397.43 | +0.6% |
ZYME | Open-market buy | 25/03/20–25/03/24 | 25/03/24 | 127,198 sh3 trades | $12.92avg. | $1,643,418.54 | +0.7% |
ZYME | Open-market buy | 25/03/17–25/03/19 | 25/03/19 | 228,463 sh3 trades | $12.54avg. | $2,865,837.55 | +1.4% |
ZYME | Open-market buy | 25/03/11–25/03/13 | 25/03/13 | 1,081,980 sh3 trades | $12.12avg. | $13,118,252.48 | +6.9% |
ANAB | Open-market buy | 24/12/30–25/01/02 | 25/01/02 | 85,098 sh3 trades | $12.92avg. | $1,099,798.22 | +1.1% |
NUVB | Open-market buyAmendment | 23/09/19–23/09/21 | 23/09/22 | 5,313,100 sh3 trades | $1.26avg. | $6,711,516 | +72.2% |
NUVB | Open-market buy | 23/02/19–23/02/21 | 23/09/21 | 5,313,100 sh3 trades | $1.26avg. | $6,711,516 | +72.2% |
